Form 4: Agilon Health's Chief Markets Officer, Benjamin Shaker, Reports Stock and Options Transactions

Benjamin Shaker, Chief Markets Officer of Agilon Health, reports acquisition and disposal of common stock and options in a recent SEC Form 4 filing.

Summary

• On April 1, 2025, Benjamin Shaker, the Chief Markets Officer of Agilon Health, reported transactions involving the company's stock and options.
• Shaker acquired 428,922 shares of common stock at $0 and disposed of 885,980 shares.
• Following these transactions, Shaker beneficially owns 885,980 shares of common stock, which includes restricted stock units.
• Additionally, Shaker acquired 673,077 options with an exercise price of $4.08, exercisable starting April 1, 2025, and expiring on April 1, 2035.
• These options vest in three equal installments on each anniversary of April 1, 2025, contingent upon continued employment.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document is a standard SEC filing reporting transactions by a company insider. There is no inherent positive or negative implication.

Future Outlook

The vesting of restricted stock units and options is contingent upon continued employment, suggesting an incentive for the reporting person to remain with the company.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests. These filings are standard practice for publicly traded companies and their executives.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders, similar to practices at companies like UnitedHealth Group (UNH) and Humana (HUM).
• The vesting schedules (three equal installments annually) are typical for such equity grants, aligning with industry norms observed at companies like CVS Health and Cigna.
• The exercise price of $4.08 for the options would need to be compared to the market price of AGL stock at the time of the grant to assess its potential value, a common practice when evaluating executive compensation packages.

Stakeholder Impact

• Shareholders can monitor insider transactions to gauge management's confidence in the company's prospects.
• Employees may be indirectly affected as executive compensation structures can influence company performance and strategic decisions.

Key Dates

Keywords

Form 4, agilon health, AGL, Benjamin Shaker, Chief Markets Officer, stock options, restricted stock units, beneficial ownership, SEC filing